Gilead's Sovaldi patent under fire again from MSF coalition, this time in Europe

Fierce Pharma -------- Gilead Sciences already faces mounting investor unease and plummeting hep C sales, and now it's looking at another Sovaldi patent challenge. Patient access groups that have targeted Gilead's Sovaldi IP all over the world are back on the attack in Europe. Global charities Médecins Sans Frontières and Médecins du Monde, plus groups from the U.K., Greece, Spain, France and Ireland are lodging a protest on Sovaldi, claiming that the med’s patents keep millions of patients from getting needed treatment. Aliénor Devalière, EU policy advisor for MSF’s Access Campaign, added in statement the “science behind” the drug “isn’t new.” In all, 30 groups from 17 countries are joining together to target Sovaldi's exclusive hold on its market in Europe. To learn more click on the picture below to read the article.